GlassScriptPhysician profile
Amanda L Glenn
NPI 1750710513
$3,746.09
in general payments reported to CMS, 2019-2025
35 companies · $1,138 in 2025
The $1,138 reported for 2025 was more than what 82% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $410 · 2023: $1,262 · 2024: $936 · 2025: $1,138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,336.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $352.36 | 2022-2025 | |
| Abbvie INC. | $332.12 | 2022-2025 | |
| Lilly USA, LLC | $292.37 | 2022-2025 | Amyvid, Kisunla, Reyvow |
| Teva Pharmaceuticals USA, INC. | $215.84 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Alexion Pharmaceuticals, INC. | $193.23 | 2023-2025 | Ultomiris, Soliris |
| Merz Pharmaceuticals, LLC | $180.08 | 2022-2025 | Xeomin, Inbrija |
| Acadia Pharmaceuticals INC | $159.50 | 2023-2025 | Nuplazid |
| Eisai INC. | $153.85 | 2022-2025 | |
| Amgen INC. | $152.61 | 2023-2025 | Repatha, Aimovig |
| Ceribell, INC. | $144.30 | 2025 | Pocket Eeg Device |
| Pfizer INC. | $140.14 | 2024-2025 | |
| Medtronic, INC. | $128.33 | 2023 | Penditure |
| Celgene Corporation | $126.26 | 2023-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $116.79 | 2023-2024 | Hyqvia, Gammagard |
| Averitas Pharma INC. | $108.00 | 2023-2025 | Qutenza |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $102.45 | 2023-2024 | Mavenclad |
| Argenx US, INC. | $98.65 | 2023-2025 | Vyvgart Hytrulo |
| Neurocrine Biosciences, INC. | $94.67 | 2023-2024 | Ingrezza, Ongentys |
| Amneal Pharmaceuticals LLC | $85.29 | 2023-2025 | Ongentys, Rytary, Ongentys 50mg Capsules 30 |
| Biohaven Pharmaceutical Holding Company LTD. | $61.88 | 2022 | |
| Ge Healthcare | $57.36 | 2023-2025 | |
| Csl Behring | $57.28 | 2024-2025 | Hizentra |
| Jazz Pharmaceuticals INC. | $53.60 | 2022-2023 | |
| Grt US Holding, INC. | $43.61 | 2022 | |
| Upsher-Smith Laboratories LLC | $41.56 | 2022 | |
| Sunovion Pharmaceuticals INC. | $41.24 | 2022 | |
| Collegium Pharmaceutical, INC. | $36.24 | 2023 | Belbuca |
| Biogen, INC. | $32.96 | 2023-2025 | Skyclarys, Leqembi |
| Inspire Medical Systems, INC. | $24.94 | 2024 | Inspire |
| Orthofix Medical, INC. | $24.92 | 2025 | Cervical-Stim |
| Astrazeneca Pharmaceuticals LP | $22.92 | 2025 | Wainua |
| Otsuka America Pharmaceutical, INC. | $22.65 | 2024 | Rexulti |
| Novartis Pharmaceuticals Corporation | $18.16 | 2023 | |
| Lundbeck LLC | $15.89 | 2024 | Vyepti |
| Neurelis, INC. | $14.04 | 2024 | Valtoco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Glenn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.